Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can blocking a cancer cell survival protein open a new path for colorectal cancer?

NCT ID NCT07813884

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 18, 2026 · Updated 3 times

Summary

Researchers are exploring whether an experimental compound called BPR001-615 can reduce the growth of colorectal cancer cells taken directly from patients during surgery. The study also measures levels of a protein called BiP in blood and tumor tissue to see whether it could serve as a future biomarker. Fifteen adults having surgery for colorectal adenocarcinoma provide a small blood sample and a piece of tumor tissue that would otherwise be discarded. The compound is tested only in the laboratory on those cells, not given to participants, and the results will not affect their care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
BPR001-615, an experimental compound that blocks the stress protein BiP
What this could lead to
If the compound slows cancer cell growth in the lab, it could point toward future BiP-targeted treatments for colorectal cancer. The blood test could also help researchers identify patients who might benefit from such treatments.
What could go wrong
This is a small laboratory study of 15 tumor samples, so results may not reflect how the compound behaves in living patients. The compound is not given to participants, and any findings would need years of further testing before reaching the clinic.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older. * Histologically confirmed colorectal adenocarcinoma. * Planned surgical resection of the primary colorectal tumor at Nice University Hospital. Exclusion Criteria: * Digestive tumor other than an adenocarcinoma, including a neuroendocrine tumor, lymphoma, gastrointestinal stromal tumor, or metastasis from another primary cancer. * Intraoperative or pathological findings showing a diagnosis other than colorectal adenocarcinoma.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal adenocarcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal adenocarcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU de Nice

    RECRUITING

    Nice, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.